Table 1.
Demographics and trough concentration results of children taking 50 mg dolutegravir.
| Dose (as film-coated tablet) | 50 mg |
| Number of children with TDM samples on dose (female) | 20 (13) |
| Ethnicity Black African; mixed Black African-white | 18; 2 |
| Means of infection (MTCT; unknown) | 9; 11 |
| Total plasma concentration samples | 76 |
| Weight (kg) | 30.65 (27.68–34.06) |
| Age (years) [IQR; range] | 10.0 (10.0–10.25; 5.9–13.8) |
| The median (range) follow-up∗ | 1.65 (0–2.07) years |
| Total follow-up time | 23.8 treatment years |
| DTG Ctrough (mg/l)∗∗ | 1.93 (32) |
| Reference Ctrough fasted children (mg/l)† | 0.72 (44) |
| Reference Ctrough fed adults (mg/l)¥ | 1.11 (46) |
| Individuals with viral blip | 2/20 |
Median (IQR) for weight and age and geometric mean Ctrough (CV%); Ctrough: concentration at the end of dosing interval (T = 24 h); MTCT: mother to child transmission. For our study this concentration is extrapolated to T = 24 h from a TDM sample.
∗Time between the first TDM sample and last data entry.
∗∗Mostly without regards to food.
†Calculated from fasted children receiving 50 mg in the ODYSSEY trial.
¥Fed adults [3].